Nicolaas P M Schaap

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1291161/publications.pdf

Version: 2024-02-01

168 papers	5,460 citations	87401 40 h-index	120465 65 g-index
171 all docs	171 docs citations	171 times ranked	7396 citing authors

#	Article	IF	Citations
1	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplantation, 2022, 57, 215-223.	1.3	36
2	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€‡ (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	1.2	18
3	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine, 2022, 11, 3541.	1.0	4
4	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia, 2021, 35, 1586-1596.	3.3	57
5	IL-15 superagonist N-803 improves IFNÎ³ production and killing of leukemia and ovarian cancer cells by CD34+â€‰progenitor-derived NK cells. Cancer Immunology, Immunotherapy, 2021, 70, 1305-1321.	2.0	27
6	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 917-927.	1.3	8
7	Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunology, Immunotherapy, 2021, 70, 3167-3181.	2.0	13
8	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 2021, 5, e553.	1.2	7
9	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere, 2021, 5, e562.	1.2	20
10	Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1964-1970.	1.3	6
11	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 686-693.	0.2	2
12	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2021, 56, 2445-2453.	1.3	6
13	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia, 2021, 35, 3551-3560.	3.3	40
14	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 2021, 56, 2367-2381.	1.3	1
15	CD34 ⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg ^{null} mice. OncoImmunology, 2021, 10, 1981049.	2.1	13
16	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. Blood, 2021, 138, 2576-2576.	0.6	0
17	Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1. Blood, 2021, 138, 2901-2901.	0.6	0
18	A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party. Blood, 2021, 138, 3937-3937.	0.6	2

#	Article	IF	Citations
19	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation, 2020, 55, 356-366.	1.3	12
20	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2â€‰Gy) as conditioning prior to allogeneic stem cell transplantation in patients (â‰¥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2020, 55, 729-739.	1.3	4
21	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplantation, 2020, 55, 884-890.	1.3	13
22	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. OncoImmunology, 2020, 9, 1843247.	2.1	48
23	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. Bone Marrow Transplantation, 2020, 55, 2308-2318.	1.3	12
24	Management of myelofibrosis after ruxolitinib failure. Annals of Hematology, 2020, 99, 1177-1191.	0.8	62
25	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	2.0	96
26	Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunology, Immunotherapy, 2020, 69, 2259-2273.	2.0	4
27	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEKâ€NUP214 shows a favourable outcome when performed in first complete remission. British Journal of Haematology, 2020, 189, 920-925.	1.2	16
28	Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Frontiers in Immunology, 2020, 11, 584520.	2.2	11
29	Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematologica Polonica, 2020, 51, 73-80.	0.1	6
30	Allograft and patient survival after sequential HSCT and kidney transplantation from the same donorâ€"A multicenter analysis. American Journal of Transplantation, 2019, 19, 475-487.	2.6	14
31	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, 2008-2016.	2.0	20
32	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2134-2142.	2.0	52
33	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation, 2019, 54, 2060-2071.	1.3	6
34	Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations. Frontiers in Immunology, 2019, 10, 880.	2.2	17
35	Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Medicine (United States), 2019, 98, e14290.	0.4	20
36	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 522-528.	2.0	48

#	Article	IF	Citations
37	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€“ a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	1.2	82
38	Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 712-719.	2.0	28
39	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-NaÃ¯ve or were Previously Treated with Ruxolitinib. Blood, 2019, 134, 668-668.	0.6	16
40	Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.. Journal of Clinical Oncology, 2019, 37, 7057-7057.	0.8	9
41	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clinical Hematology International, 2019, 1, 58.	0.7	46
42	Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party. Blood, 2019, 134, 4483-4483.	0.6	0
43	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biology of Blood and Marrow Transplantation, 2018, 24, 930-936.	2.0	11
44	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica, 2018, 103, 514-521.	1.7	70
45	Immune checkpoint molecules in acute myeloid leukaemia: managing the doubleâ€edged sword. British Journal of Haematology, 2018, 181, 38-53.	1.2	42
46	Shortâ€term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anaemia. British Journal of Haematology, 2018, 180, 459-462.	1.2	2
47	Relatively favorable outcome after allogeneic stem cell transplantation for BCRâ€ABL1â€positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2018, 93, 31-39.	2.0	13
48	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. Biology of Blood and Marrow Transplantation, 2018, 24, 507-513.	2.0	10
49	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 666-677.	2.0	45
50	Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice. Blood, 2018, 131, 202-214.	0.6	40
51	Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. International Journal of Radiation Oncology Biology Physics, 2018, 102, 515-526.	0.4	25
52	The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2. Haematologica, 2018, 103, 2008-2015.	1.7	19
53	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncology, 2018, 4, 1245.	3.4	97
54	Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. OncoImmunology, 2018, 7, e1488565.	2.1	41

#	Article	IF	Citations
55	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. Blood, 2018, 132, 708-708.	0.6	4
56	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors â€" a Retrospective Study By the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 3465-3465.	0.6	0
57	Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2017, 23, 4107-4118.	3.2	139
58	Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responsesex vivo. OncoImmunology, 2017, 6, e1285991.	2.1	20
59	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Journal of Hematology and Oncology, 2017, 10, 20.	6.9	43
60	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic LeukemiaÂ- A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 667-675.e2.	0.2	12
61	Centre characteristics and procedureâ€related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). British Journal of Haematology, 2017, 178, 521-533.	1.2	26
62	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	2.2	243
63	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2017, 177, 759-765.	1.2	38
64	Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Bone Marrow Transplantation, 2017, 52, 1107-1112.	1.3	19
65	Standard Versus Single Dose-Daily Fractionated Total Body Irradiation Schedules Prior to Allotransplant for Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). International Journal of Radiation Oncology Biology Physics, 2017, 99, S177-S178.	0.4	0
66	A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. Bone Marrow Transplantation, 2017, 52, 1378-1383.	1.3	21
67	Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. Journal of Clinical Apheresis, 2017, 32, 295-301.	0.7	8
68	Longâ€term followâ€up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2016, 122, 1880-1887.	2.0	31
69	On Good Neighbors and Distant Friends in the Online Era. Transportation Research Record, 2016, 2566, 55-63.	1.0	0
70	Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 2016, 51, 1259-1261.	1.3	3
71	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia, 2016, 30, 2047-2054.	3.3	59
72	Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. Journal of Virology, 2016, 90, 10022-10038.	1.5	31

#	Article	IF	Citations
73	Thiotepaâ€based versus total body irradiationâ€based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. European Journal of Haematology, 2016, 96, 90-97.	1.1	16
74	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. Journal of Immunology, 2016, 197, 2715-2725.	0.4	43
75	Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. Journal of Hematology and Oncology, 2016, 9, 118.	6.9	50
76	Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses. Biology of Blood and Marrow Transplantation, 2016, 22, 1000-1008.	2.0	42
77	Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 179-182.	2.0	28
78	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. Blood, 2016, 128, 2293-2293.	0.6	2
79	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. Blood, 2016, 128, 4657-4657.	0.6	7
80	Salvage Use of Ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties. Blood, 2016, 128, 4659-4659.	0.6	8
81	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. Blood, 2016, 128, 522-522.	0.6	0
82	A Comparison of Fractionated Myeloablative Total Body Irradiation Schedules Combined with Chemotherapy As Conditioning for Allograft Bone Marrow Transplantation in Patients with Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 981-981.	0.6	0
83	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. Blood, 2016, 128, 4655-4655.	0.6	1
84	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 4663-4663.	0.6	0
85	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. Blood, 2016, 128, 4685-4685.	0.6	2
86	LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application. Haematologica, 2015, 100, e419-e422.	1.7	14
87	Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival. Haematologica, 2015, 100, e508-e510.	1.7	10
88	Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18. Journal of Immunotherapy, 2015, 38, 145-154.	1.2	39
89	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk groupâ€“an observational analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2015, 50, 1063-1068.	1.3	41
90	The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34⁺Hematopoietic Stem and Progenitor Cells. Stem Cells and Development, 2015, 24, 2886-2898.	1.1	29

#	Article	IF	Citations
91	Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e143-e146.	0.6	21
92	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	1.7	203
93	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica, 2015, 100, 489-496.	1.7	50
94	Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. Journal of Virology, 2015, 89, 9499-9510.	1.5	58
95	Combined IL-15 and IL-12 drives the generation of CD34‹sup›+‹/sup›-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. OncoImmunology, 2015, 4, e1017701.	2.1	44
96	Comparison of upfront tandem autologousâ€“allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. Bone Marrow Transplantation, 2015, 50, 802-807.	1.3	13
97	siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunology, Immunotherapy, 2015, 64, 645-654.	2.0	42
98	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Bone Marrow Transplantation, 2015, 50, 822-828.	1.3	17
99	A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients. Blood, 2015, 126, 1357-1357.	0.6	31
100	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. Blood, 2015, 126, 863-863.	0.6	23
101	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 2021-2021.	0.6	0
102	Immunotherapeutic approaches to treat multiple myeloma. Human Vaccines and Immunotherapeutics, 2014, 10, 896-910.	1.4	7
103	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica, 2014, 99, 1492-1498.	1.7	19
104	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
105	The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34‹sup›+‹/sup› Hematopoietic Progenitor Cells. Stem Cells and Development, 2014, 23, 955-967.	1.1	53
106	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2014, 49, 950-954.	1.3	5
107	Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. European Journal of Cancer, 2014, 50, 411-417.	1.3	60
108	Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1448-1450.	2.0	7

#	Article	IF	Citations
109	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood, 2014, 124, 3490-3500.	0.6	103
110	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica, 2014, 99, 1582-1590.	1.7	36
111	Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers. Blood, 2014, 124, 2554-2554.	0.6	7
112	Non Interventional Prospective Clinical Study on Peripheral Blood Stem Cell Mobilization in Patients with Relapsed Lymphomas. Blood, 2014, 124, 3852-3852.	0.6	0
113	The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis. Blood, 2014, 124, 1209-1209.	0.6	1
114	The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1 Stimulates Expression of NK Cell Related Transcription Factors, Thereby It Facilitates Generation of Highly Functional NK Cells in Vitro. Blood, 2014, 124, 3833-3833.	0.6	1
115	Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia, 2013, 27, 604-609.	3.3	105
116	Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunology, Immunotherapy, 2013, 62, 1381-1392.	2.0	61
117	Human secondary lymphoid organs typically contain polyclonally-activated proliferating regulatory T cells. Blood, 2013, 122, 2213-2223.	0.6	28
118	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunology, Immunotherapy, 2013, 62, 285-297.	2.0	111
119	Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 274-282.	2.0	43
120	Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplantation, 2013, 48, 837-842.	1.3	8
121	Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice. PLoS ONE, 2013, 8, e64384.	1.1	71
122	Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT. Blood, 2013, 122, 2123-2123.	0.6	1
123	No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study. Blood, 2013, 122, 2132-2132.	0.6	2
124	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). Blood, 2013, 122, 661-661.	0.6	13
125	Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma. An EBMT Analysis. Blood, 2013, 122, 920-920.	0.6	2
126	The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In MDS/sAML: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party. Blood, 2013, 122, 922-922.	0.6	9

#	Article	IF	Citations
127	Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells. Blood, 2013, 122, 3269-3269.	0.6	0
128	Donor Cell Derived Leukemia: Description Of 38 Cases and a Case Control Study. Blood, 2013, 122, 914-914.	0.6	0
129	Influence Of DNA Methyltransferese Inhibitors On The Anti-Leukemic Effect Of Umbilical Cord Blood Derived NK Cells Against Acute Myeloid Leukemia. Blood, 2013, 122, 4496-4496.	0.6	0
130	Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT. Blood, 2013, 122, 542-542.	0.6	5
131	Ex Vivo Generation Of Functional Plasmacytoid and Myeloid Dendritic Cells Is Strongly Promoted By The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1. Blood, 2013, 122, 2025-2025.	0.6	0
132	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. Blood, 2013, 122, 2092-2092.	0.6	0
133	B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation. Journal of Immunology, 2012, 189, 39-49.	0.4	60
134	Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs. Bone Marrow Transplantation, 2012, 47, 1229-1234.	1.3	5
135	Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood, 2012, 119, 6219-6225.	0.6	97
136	Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT. Blood, 2012, 120, 233-233.	0.6	1
137	Long-Term Follow-up of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML): A Survey of 3567 Patients From the Acute Leukemia Working Party of the EBMT.. Blood, 2012, 120, 3112-3112.	0.6	2
138	Polymorphisms in CCR6 Are Associated with Chronic Graft-versus-Host Disease and Invasive Fungal Disease in Matched-Related Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1443-1449.	2.0	15
139	Concurrent Detection of Circulating Minor Histocompatibility Antigen-Specific CD8+ T Cells in SCT Recipients by Combinatorial Encoding MHC Multimers. PLoS ONE, 2011, 6, e21266.	1.1	6
140	PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation. Cancer Research, 2011, 71, 5111-5122.	0.4	140
141	Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. Bone Marrow Transplantation, 2011, 46, 1071-1076.	1.3	32
142	Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process. PLoS ONE, 2011, 6, e20740.	1.1	199
143	Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-Versus-Host-Disease Upon Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4136-4136.	0.6	0
144	CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia, 2010, 24, 583-591.	3.3	26

#	Article	IF	Citations
145	siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigenâ€“specific CD8+ T cells. Blood, 2010, 116, 4501-4511.	0.6	133
146	Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced-Intensity Conditioning Creates a Platform for Immunotherapy with Donor Lymphocyte Infusion and Recipient Dendritic Cell Vaccination in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 320-332.	2.0	22
147	High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE, 2010, 5, e9221.	1.1	150
148	Intestinal Damage Determines the Inflammatory Response and Early Complications in Patients Receiving Conditioning for a Stem Cell Transplantation. PLoS ONE, 2010, 5, e15156.	1.1	83
149	NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2009, 44, 243-248.	1.3	57
150	Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion, 2008, 48, 1478-1485.	0.8	200
151	KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Molecular Immunology, 2008, 45, 3631-3638.	1.0	33
152	â€˜Blindâ€™ transfusion of blood products in exsanguinating trauma patients. Resuscitation, 2007, 73, 382-388.	1.3	81
153	Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. Bone Marrow Transplantation, 2007, 40, 355-359.	1.3	23
154	Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplantation, 2007, 40, 585-592.	1.3	16
155	The Balance in Chimerism between T Cells and Blood Dendritic Cells in Relapsed CML Patients Influences the Induction of Alloreactivity Following Donor Lymphocyte Infusion.. Blood, 2006, 108, 5139-5139.	0.6	0
156	Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplantation, 2004, 33, 1115-1121.	1.3	10
157	Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. Leukemia, 2003, 17, 621-629.	3.3	80
158	Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia, 2002, 16, 13-21.	3.3	40
159	Neuropsychiatric symptoms during cefepime treatment. International Journal of Clinical Pharmacy, 2001, 23, 36-36.	1.4	12
160	Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia, 2001, 15, 1339-1346.	3.3	55
161	Red blood cell phenotyping is a sensitive technique for monitoring chronic myeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion. British Journal of Haematology, 2000, 108, 116-125.	1.2	27
162	Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplantation, 2000, 26, 17-22.	1.3	17

#	Article	IF	Citations
163	Impact of Chemotherapy on the Mobilisation, Harvest and Economic Costs of Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma. Leukemia and Lymphoma, 2000, 37, 551-560.	0.6	5
164	Cost Analysis of Autologous Peripheral Stem Cell Transplantation Versus Autologous Bone Marrow Transplantation for Patients with Non Hodgkin's Lymphoma and Acute Lymphoblastic Leukaemia. Leukemia and Lymphoma, 1999, 36, 33-43.	0.6	7
165	Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone Marrow Transplantation, 1998, 22, 13-19.	1.3	14
166	Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplantation, 1997, 19, 791-794.	1.3	27
167	Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase. Bone Marrow Transplantation, 1997, 19, 1205-1212.	1.3	17
168	Outcome of transplantation for standardâ€risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. British Journal of Haematology, 1997, 98, 750-759.	1.2	41